Diligence memo · auto-generated · as of July 2, 2026
Autobahn Therapeutics, Inc.
Autobahn Therapeutics, Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Autobahn Therapeutics, Inc. operates in Biotechnology, based in SAN DIEGO.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Autobahn Therapeutics, Inc. has raised $101M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $101M on 2024-06-20.
Most recent recorded round closed around 2024-06-20.
Valuation (modeled)modeled
Provath models Autobahn Therapeutics, Inc. at approximately $1.1B (range $457M–$1.6B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.56× the median modeled value of Series D+ Biotechnology companies in 2022–2024 (75 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 2.0 yr ago; this sector typically re-raises about every 14 months.
Slightly overdue versus sector cadence.
Comparablesmixed
Capital scale ranks ahead of 90% of Biotechnology peers (4293 compared).
Modeled value ranks above 90% of those peers.
Closest niche peers: Areteia Therapeutics, Inc., GIO World Health Ltd, Crinetics Pharmaceuticals, Inc., 2seventy bio, Inc., Gio World Health (Europe) Sa.
Peoplefiled
10 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.